{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"357"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"201"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"description":"Eastern Cooperative Oncology Group (ECOG) performance score, laboratory values, vital sign measurements and reported adverse events (AEs) were collected and assessed to evaluate the safety of therapy throughout the study. An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to EOT (up to approximately 42.9 months).","id":"OG000","title":"Ixazomib+ Lenalidomide + Dexamethasone"},{"description":"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first (up to approximately 41 months).","id":"OG001","title":"Placebo + Lenalidomide + Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included all randomized participants who received at least 1 dose of any study drug, regardless of their randomized treatment.","reportingStatus":"POSTED","timeFrame":"From the date of signing of the informed consent form through 30 days after the last dose of study drug up to approximately 115 months","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}